The CRISPR Medicine Conference
Important Dates for the CRISPR Medicine Conference 2024
Before the Event:
- September 1st, 2023: Registration & abstract submissions open
- January 12th, 2024: Early bird registration deadline (EXTENDED to January 19th)
- January 24th, 2024: Abstract submission deadline (EXTENDED to January 31st)
- February 29th, 2024: Oral and poster notifications & final programme available
- March 1st, 2024: Travel grant notification
- April 8th, 2024: Registration deadline in-person event (EXTRA Tickets available)
- April 21st, 2024: Registration deadline virtual event
- April 22nd, 2024: Abstract publication in the CRISPR Medicine News portal
Event:
- April 22nd, 2024: Virtual event
- April 23-25th, 2024: In-person event in Copenhagen, Denmark
View the Final CRISPRMED24 Program here
Access the CRISPRMED24 Live App here
First version of the Abstract Book is now available
Welcome
The first CRISPR Medicine Conference will take place in Copenhagen, Denmark, on the 23-25th April 2024 (virtual event 22nd April). This event will bring European CRISPR research to the forefront, with 6 main tracks that cover the most important topics in the therapeutic gene-editing field: Tools, Delivery, Safety, Functional Genomics, Standards and Regulations, Pre-clinical Research and Clinical Trials.
This will be a hybrid event with a strong focus on in-person attendance and on-demand virtual content. The conference will include talks by reputable speakers from academia and industry, as well as several workshops focused on developing useful skills for a successful career in gene editing.
You can register to attend the event and submit an abstract directly through this website. Our separate in-person and virtual poster sessions will allow any type of attendee to present and discuss their research with their peers. The top-scoring abstracts will be presented as oral presentations and the authors will be interviewed by CRISPR Medicine News, which boasts an audience of over 25,000 readers per month.
Once you have registered, you will be able to explore the content and see the list of participants.
Meet the confirmed CRISPRMED24 attendees here.
If you have any questions, please refer to our FAQ section or contact CRISPRMED24 staff at info@crisprmedicineconference.com.
**CRISPRMED24 Newsletter - Sign up here**
If you can not attend this year, reserve already the dates for the 2nd CRISPR Medicine Conference, CRISPRMED25 - Stay updated here.
Abstract review panel:
- Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
- Toni Cathomen, Prof. and Director of the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg, Germany
- Alessia Cavazza, Ass. Prof., Group Leader, University College London Great Ormond Street Institute of Child Health, England
- Anna Cereseto, Prof. and Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy
- Ayal Hendel, Principal Investigator at The Mina and Everard Goodman Faculty of Life Sciences at Bar-Ilan University, Israel
- Jan Gorodkin, Professor and Group Leader at the University of Copenhagen, Denmark
- Marianne Carlon, Ass. Prof. at the Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) and the Center for Molecular Medicine of the KU Leuven Faculty of Medicine, Belgium
- Paula Rio, Head of the Bone Marrow Failure Unit at CIEMAT/CIBERER/IIS-FJD at the Universidad Autónoma in Madrid, Spain
- Pia Johansson, Scientific Coordinator of the Cell and Gene Therapy Core at Lund University, Sweden
Keynote Speaker
Luigi Naldini
San Raffaele Telethon Institute for Gene Therapy and San Raffaele University, Milan, Italy
Luigi Naldini, M.D., Ph.D., is Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy (Milan, Italy). He received his medical degree from the University of Turin (Italy) and his PhD from the University “La Sapienza” of Rome (Italy).
For the past 25 years he has pioneered the development and application of lentiviral vectors for gene therapy, which have become one of the most widely used tools in biomedical research and, upon recently entering clinical testing, are providing a long-sought hope of cures for several currently untreatable and otherwise deadly human diseases. Throughout this time, he has continued to investigate new strategies to overcome the major hurdles to safe and effective gene transfer, bringing about innovative solutions that are not only being translated into new therapeutic strategies for genetic disease and cancer, but have also yielded novel insights into haematopoietic stem cell function, induction of immunological tolerance, and tumour angiogenesis.
Professor Naldini's work has also contributed to advancing the use of artificial nucleases for targeted genome editing in cell- and gene therapy. To date, he has published over 290 scientific papers, and his SCOPUS Author h-index is 105. He is also co-founder of three innovative biotech start-up companies: Genenta (recently listed on Nasdaq), Epsilen Bio (now acquired by Chroma Medicine) and Genespire.
Sponsors
Confirmed Speakers
Alessia Cavazza
University College London, United Kingdom
Group Leader and Associate Professor in Gene Therapy at University College London's Great Ormond Street Institute of Child Health.
Alvin Luk
HuidaGene Therapeutics, Inc.
Alvin Luk is Co-Founder, CEO, and Head of Medical at HuidaGene Therapeutics, Inc.
Alvin will speak at the CRISPRMED24 Virtual Event 22nd April.
André Cohnen
Bayer AG
Head of Genomic Medicine at Bayer.
Andrew Bellinger
Verve Therapeutics
CSO at Verve Therapeutics and Co-Founder at Corner Therapeutics
Angelo Lombardo
San Raffaele - Telethon Institute for Gene Therapy, Italy
Group Leader at the San Raffaele - Telethon Institute for Gene Therapy (SR-Tiget) and Professor at the Vita-Salute San Raffaele University in Milano, Italy. Co-founder of Chroma Medicine.
Antonio Casini
Alia Therapeutics
Antonio is a Co-Founder and CTO at Alia Therapeutics.
Anna Cereseto
University of Trento, Italy
Professor. and Vice-Director of Department at University of Trento, and Co-Founder of Alia Therapeutics.
Ashley Jacobi
Integrated DNA Technologies (IDT)
Director of Applications and Market Development at IDT.
Avencia Sanchez-Mejias
INTEGRA Therapeutics
CEO and Co-founder at INTEGRA Therapeutics.
Ayal Hendal
Bar-Ilan University, Israel
Principal Investigator and Group leader at Bar-Ilan University, Israel.
Ben Kleinstiver
Harvard Medical School and Massachusetts General Hospital
Assistant Professor at the Center for Genomic Medicine, Harvard Medical School. MGH Research Scholar at Massachusetts General Hospital.
Bernhard Schmierer
Karolinska Institutet, Sweden
Head of the CRISPR Functional Genomics unit at the SciLifeLab and Karolinska Institutet in Stockholm, Sweden.
Brian Cosgrove
Tune Therapeutics
Brian Cosgrove is a Principal Scientist at Tune Therapeutics and the research lead for the Hepatitis B program.
Brian will speak at the CRISPRMED24 Virtual Event 22nd April.
Daniel Schraivogel
EMBL
Research Staff Scientist at EMBL.
LinkedIn Lab WebpageFan Zhou
GenScript Biotech
Senior scientist of molecular biology at GenScript Biotech.
Fiona M. Behan
GlaxoSmithKline Pharma
Scientific Director at GlaxoSmithKline Pharma.
Hao Wu
Full Circles Therapeutics/Stellate DNA, USA
Co-Founder and CSO of Full Circles Therapeutics, as well as the Director of Stellate DNA.
Iván Hernández
Countagen
Iván is the CSO of Countagen AB.
Iván will speak at the CRISPRMED24 Virtual Event 22nd April.
Jan Gorodkin
University of Copenhagen, Denmark
Prof. and Group leader at University of Copenhagen, Denmark.
Jan Nelis
Ariya Bio
Co-Founder and Project Lead at Ariya Bio.
Jin Chen
Altos Labs, USA
Principal Investigator at Altos Labs and an assistant professor at UT Southwestern Medical Center in Dallas, USA.
Jonas Hink
SNIPR Biome
Chief Medical Officer at SNIPR Biome.
Julien Valton
Cellectis
Vice-President of Gene Therapy at Cellectis.
Karim Benabdellah
Fundación Pública Andaluza Progreso y Salud, Spain.
Senior Scientist at the GENyO. Pfizer-University of Granada-Junta de Andalucia Center for Genomics and Oncological Research in Granada, Spain.
Karina Thorn
Novo Nordisk
Corporate Vice President, PhD, Head of Research, Global Nucleic Acid Therapies (GNAT) at Novo Nordisk.
Kevin Holden
Synthego
Head of Science & Applied Research at Synthego.
Laura Sepp-Lorenzino
Intellia Therapeutics
Executive Vice President and Chief Scientific Officer at Intellia Therapeutics.
Manuel Kaulich
Goethe University Frankfurt, Germany
Prof. at Goethe University Frankfurt, Germany and CSO at Vivlion.
Marcello Maresca
AstraZeneca AB
Senior Director of Genome Engineering Team at AstraZeneca.
Marianne Carlon
Catholic University (KU) Leuven, Belgium
Ass. Prof. at the Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE) and the Center for Molecular Medicine of the KU Leuven Faculty of Medicine.
Google Scholar ORCIID LinkedIn BREATHE Webpage KU Leuven Webpage
Michael Krohn
Akribion Genomics
Michael Krohn is Co-CEO at Akribion Genomics.
Michael will speak at the CRISPRMED24 Virtual Event 22nd April.
Nikhil Gupta
Cancer Research UK
Principal Scientist at the Joint AstraZeneca-Cancer Research Horizons Functional Genomics Centre, UK.
Paul Diehl
Cellecta
Chief Operating Officer and Director of Business Development at Cellecta.
Paula Rio
CIEMAT/CIBERER/IIS-FJD, Universidad Autónoma de Madrid
Head of the Bone Marrow Failure Unit at CIEMAT/CIBERER/IIS-FJD at the Universidad Autónoma in Madrid.
Pia Johansson
Lund University, Sweden
Scientific Coordinator of the Cell and Gene Therapy Core at Lund University.
Raoul Hennig
BioSpring
Project Lead in cGMP manufacturing at BioSpring.
Rasmus O. Bak
Aarhus University, Denmark
Ass. Prof. at the Department of Biomedicine at Aahrus University and Co-Founder of UNIKUM Therapeutics.
Roberto Nitsch
AstraZeneca
Associate Director of Gene Therapy at Astra Zeneca.
Samantha Maragh
National Institute of Standards & Technology, USA
Leader of the Gene Editing Program at the National Institute of Standards & Technology.
Seung Wook Yang
Amgen
Principal Scientist at Amgen.
Google Scholar ORCIID LinkedIn Company WebpageSidsel Alsing
Samplix
Field Application Scientist at Samplix.
Simon Reed
Broken String Biosciences
Co-Founder and CSO at Broken String Biosciences.
Simone Spuler
Charité Universistätsmedizin Berlin / Max Delbrück Center
Full Professor at Charité Universistätsmedizin Berlin and a Group Leader at Max Delbrück Center, in Germany.
LinkedIn Google Scholar ORCIID Lab WebpageStefano Stella
Ensoma
Vice-President of Gene Editing at Ensoma, Founder and Chief Technology Officer at Twelve Bio, Ass. Prof. at the Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Denmark.
Toni Cathomen
University of Freiburg, Germany
Prof. and Director at the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg.
Vasileios Georgakakos
Clean Cells
Veronika jerkerle
European Medicines Agency (EMA)
Veronika Jekerle is Head of Pharmaceutical Quality, Human Division, at the European Medicines Agency (EMA), Amsterdam, NL.
Waseem Qasim
UCL Great Ormond Street Institute of Child Health, UK
Consultant in Paediatric Immunology and a Prof. of Cell & Gene Therapy at the Infection, Immunity & Inflammation Department at University College London (UCL) Great Ormond Street (GOS) Institute of Child Health
Xavier Duportet
Eligo Bioscinece
CEO and Co-founder at Eligo Bioscience.
Yonglun Luo
Aarhus University, Denmark
Prof. of Gene and Stem Cell Technology at Aarhus University, Denmark and Executive Director at the Lars Bolund Institute of Regenerative Medicine, China.
Zhenya Ivakine
The Hospital for Sick Children
Group Leader at The Hospital for Sick Children in Toronto, Canada.
Scientific Committee
· Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca, Sweden
· Toni Cathomen, Prof. and Director of the Institute for Transfusion Medicine and Gene Therapy, University of Freiburg, Germany
· Alessia Cavazza, Ass. Prof., Group Leader, University College London Greater Ormond Street Institute of Child Health, England
· Anna Cereseto, Prof. and Vice-Director, Centre for Integrative Biology (CIBIO), University of Trento, Italy at University of Trento, Italy
· Karen O´Hanlon Cohrt, Chief Editor CMN
Organising Committee
· Karen O´Hanlon Cohrt, Chief Editor, CRISPR Medicine News
· Gorm Palmgren, Science Writer and Editor, CRISPR Medicine News
· Jens-Ole Bock, Founder, CRISPR Medicine News
· Antonio Carusillo, Science Writer, CRISPR Medicine News
· Manel Lladó, Science Writer, CRISPR Medicine News
Attending Institutions and Companies
Attendees (confimed) - Investors
Location
Copenhagen, Denmark
Registration period
August 1, 2023 - 00:00 until April 25, 2024 - 10:00
Submission period
August 1, 2023 - 12:00 until April 25, 2024 - 12:00
Contact us
If you have any questions, please contact info@crisprmedicineconference.com .